about
Engineering opportunities in cancer immunotherapyTrial Watch: Adoptive cell transfer for oncological indicationsSynthetic biology approaches to engineer T cellsThe Evolution of T-cell Therapies for Solid MalignanciesNext-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneityTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsAdoptive T Cell Therapy Targeting CD1 and MR1The next steps in next-gen sequencing of cancer genomesNovel immunotherapies for hematologic malignanciesImproving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationSynthetic Nanoparticles for Vaccines and ImmunotherapyManufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapiesEngineering T Cells to Functionally Cure HIV-1 InfectionCish actively silences TCR signaling in CD8+ T cells to maintain tumor toleranceCRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation.Improving the safety of cell therapy with the TK-suicide geneGeneration of knock-in primary human T cells using Cas9 ribonucleoproteins.Lentiviral vectors, two decades later.Classification of current anticancer immunotherapiesTransfer of mRNA Encoding Invariant NKT Cell Receptors Imparts Glycolipid Specific Responses to T Cells and γδT CellsRational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastomaNovel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor ActivityApoptosis-induced activation of HIV-1 in latently infected cell linesSkewed Differentiation of Circulating Vγ9Vδ2 T Lymphocytes in Melanoma and Impact on Clinical Outcome.Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia.Assessment of cancer and virus antigens for cross-reactivity in human tissues.Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints.Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.2015 Guidance on cancer immunotherapy development in early-phase clinical studies.Cellular Adjuvant Properties, Direct Cytotoxicity of Re-differentiated Vα24 Invariant NKT-like Cells from Human Induced Pluripotent Stem Cells.IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cellsImproving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cellsEnhancing adoptive T cell immunotherapy with microRNA therapeutics.Adoptive Transfer of CD8+ T Cells Generated from Induced Pluripotent Stem Cells Triggers Regressions of Large Tumors Along with Immunological Memory.CAR-T Cell Therapies From the Transfusion Medicine PerspectiveRole of memory T cell subsets for adoptive immunotherapy.The modulation of Dicer regulates tumor immunogenicity in melanoma.Efficient generation of antigen-specific CTLs by the BAFF-activated human B Lymphocytes as APCs: a novel approach for immunotherapy.T cell-based targeted immunotherapies for patients with multiple myeloma.
P2860
Q26776373-8D28E103-07F7-4F56-BED3-CE1D588DFEE7Q26785545-71BA79EC-BAEA-4726-9F9B-DC3467974D59Q26798366-249A8DFD-C137-40F7-8580-3E3353A66B64Q26799372-FF5F9226-A3CD-4222-96B7-CF70E756696FQ26992272-52AA15BD-8593-4B52-913C-8401F2769AD8Q26996518-6CCF5A2F-7C8C-4A9B-AD15-A6DB04395C1AQ26998503-CBDAA311-9916-4CC5-A0B2-941EF1290D5CQ26998894-1211A6F6-572F-436F-8506-65137BC2D598Q27004436-CDF30C72-E460-4611-B8FE-F0DD7E4C478AQ28068378-0D50CA1D-72E7-4663-9BD9-0CDD00B72A22Q28085375-13EEDA4B-8BA7-4AE3-8BA2-F8B3DFDB0738Q28085769-FBE9D21F-A5A8-4AE4-A99C-8640665C4522Q28086801-7C0A62B9-436F-49D0-A63C-A006C17C9367Q28269352-31887420-D1F1-4B36-9C21-8B6E0CC220E3Q33671867-010550B6-6BDB-465C-ABBE-24A52D18AD9BQ33874986-844799CB-B5E4-42BD-BE43-5D11104DE103Q34477411-114723BA-856A-483D-A6A0-3EB8FB183F43Q34487189-036330B6-B317-486F-BA15-5682B8932271Q34539903-435892D6-21DF-423D-8DE2-9776D15E7B82Q35149637-0A813D8B-1791-41A9-80BA-728B6DCA731FQ35677421-2D8049C2-2D7F-4E27-A0E1-DDB2E11FFEDBQ35741739-DD1FF8D2-C1BA-45C9-B12F-9201B7D65FE3Q35745453-D2F507AC-9361-4F25-B78D-3D304BA8F1D4Q35747595-5B14A6CE-2CCC-4AA7-9487-E09A3F0F7FB9Q35935862-EEED221D-7E0A-47D4-9D65-69140AF950F8Q36110355-BBD8CF02-2FB5-4C11-B8FC-783362298082Q36129290-FD62462B-717A-4E52-BC53-CF685EAB1D28Q36160526-DC2FEC6D-E42A-408C-AA50-6AC2E11DCCE6Q36430680-9061963D-1A21-4AB5-9D62-B2C65A39BF7EQ36467378-F1572880-B23F-4619-B7AA-7A2E8BEC25F4Q36570136-51FB9FBF-AC47-4ED4-8D41-2B43C357106DQ36727794-3A7DECEE-54E1-4430-A8EE-2A232D2E5C13Q36777093-A38FB775-6278-4A73-9676-F82F0B027CEEQ36889204-5FA9EAB6-BCD7-42A3-B778-E96915782B8CQ37014144-0FF9762A-3F98-4296-A714-E7D01B1C303AQ37022738-DD30CEF8-0F7C-4DB6-9D99-039F94DF820EQ37263366-7664E750-1D6D-476D-AB11-066EFCCCD36CQ37565233-5FA412F0-157A-4B8D-8CFF-9E254054151CQ37718429-06F6527D-7215-4B24-9E21-91441A87A2FFQ38246639-68E93CC9-1F34-4447-AEFF-90BCBDC993C3
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Adoptive immunotherapy for cancer or viruses.
@en
type
label
Adoptive immunotherapy for cancer or viruses.
@en
prefLabel
Adoptive immunotherapy for cancer or viruses.
@en
P2093
P2860
P1476
Adoptive immunotherapy for cancer or viruses.
@en
P2093
Bruce L Levine
Carl H June
Joseph A Fraietta
Michael Kalos
Yangbing Zhao
P2860
P304
P356
10.1146/ANNUREV-IMMUNOL-032713-120136
P577
2014-01-09T00:00:00Z